Roche to Terminate Gavreto Deal With Blueprint Medicines
Blueprint will regain global commercialization rights for the RET inhibitor following Roche's decision to end the collaboration for strategic reasons.
FDA Places Partial Clinical Hold on Phase I Trial of Blueprint's CDK2 Inhibitor
The company will not enroll any new patients in the VELA trial while it investigates incidents of visual adverse events in some patients who received BLU-222.
Synthetic Control Arms Finding Stronger Footing in Precision Oncology Trials, Regulatory Submissions
In cases where randomized-controlled clinical trials aren't feasible, using real-world data to build an external control arm for comparison is becoming a more accepted solution.
Blueprint Medicines' Q1 Ayvakit Sales More Than Triple
In Q1, the precision treatment for GIST and systemic mastocytosis brought in $23.8 million compared to $7.1 million in the year-ago period.
In Brief This Week: Blueprint Medicines, AstraZeneca, Kite, Zai Lab
News items for the week of April 18, 2022.